Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Amyloidosis

ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD

This VJHemOnc podcast highlights key AL amyloidosis updates from ASH 2025. Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS…

Date: 6th February 2026

Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain

In this episode of the VJHemOnc podcast, we are joined by Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, a…

Date: 14th June 2025

Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!

Today’s podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar,…

Date: 21st February 2025

Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT

Welcome to today’s VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis…

Date: 25th June 2024

Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology

While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due…

Date: 7th March 2024

ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis

In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents….

Date: 5th January 2024

Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in…

Date: 24th November 2023

Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team

Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage….

Date: 11th July 2023

ISA 2022: meeting highlights and recent updates in amyloidosis

The 18th Meeting of the International Society of Amyloidosis (ISA) was held in Heidelberg, Germany, on 4-8 September, 2022. This…

Date: 21st October 2022

Myeloma 2022: day one highlights

At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety…

Date: 27th July 2022

Addressing unmet needs and future treatment approaches in AL amyloidosis

Amyloidosis is a heterogeneous disease that results from the deposition of abnormal protein aggregates in various tissues and organs. The…

Date: 1st July 2022

Harnessing the power of immunotherapy in myeloma and amyloidosis

The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,…

Date: 20th May 2022